Brokerages forecast that Diplomat Pharmacy Inc (NYSE:DPLO) will announce $0.23 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Diplomat Pharmacy’s earnings, with estimates ranging from $0.19 to $0.38. Diplomat Pharmacy posted earnings per share of $0.19 in the same quarter last year, which would suggest a positive year over year growth rate of 21.1%. The company is scheduled to issue its next earnings report on Monday, May 14th.
According to Zacks, analysts expect that Diplomat Pharmacy will report full year earnings of $0.98 per share for the current financial year, with EPS estimates ranging from $0.90 to $1.36. For the next fiscal year, analysts forecast that the business will post earnings of $1.15 per share, with EPS estimates ranging from $1.01 to $1.46. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Diplomat Pharmacy.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.18 EPS for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the business earned $0.08 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year.
DPLO has been the topic of a number of research reports. Mizuho boosted their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 7th. Leerink Swann boosted their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 7th. Needham & Company LLC boosted their price objective on Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. BidaskClub downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Robert W. Baird downgraded Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $24.00 to $18.00 in a research note on Thursday, November 16th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $24.79.
Diplomat Pharmacy (NYSE:DPLO) traded down $0.33 on Wednesday, hitting $21.03. The stock had a trading volume of 677,719 shares, compared to its average volume of 936,358. Diplomat Pharmacy has a 12 month low of $14.00 and a 12 month high of $27.78. The company has a quick ratio of 0.66, a current ratio of 0.97 and a debt-to-equity ratio of 0.70. The company has a market cap of $1,450.00, a P/E ratio of 61.85 and a beta of 1.32.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Advisors Preferred LLC acquired a new position in shares of Diplomat Pharmacy in the 4th quarter worth $162,000. SG Americas Securities LLC acquired a new position in shares of Diplomat Pharmacy in the 3rd quarter worth $191,000. Piedmont Investment Advisors LLC acquired a new position in shares of Diplomat Pharmacy in the 3rd quarter worth $216,000. Fox Run Management L.L.C. acquired a new position in shares of Diplomat Pharmacy in the 4th quarter worth $244,000. Finally, ETRADE Capital Management LLC acquired a new position in shares of Diplomat Pharmacy in the 4th quarter worth $276,000. Institutional investors and hedge funds own 64.52% of the company’s stock.
WARNING: This piece was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://ledgergazette.com/2018/03/14/zacks-analysts-anticipate-diplomat-pharmacy-inc-dplo-will-post-earnings-of-0-23-per-share.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.